Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

alectinib

View Patient Information
An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ALK inhibitor CH5424802
ALK inhibitor RO5424802
US brand name:Alecensa
Foreign brand name:Alecensa
Code name:AF 802
AF-802
AF802
CH 5424802
CH-5424802
CH5424802
RG 7853
RG-7853
RG7853
RO 5424802
RO-5424802
RO5424802
UNII-LIJ4CT1Z3Y
Chemical structure:5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search